# Maintenance Treatment With Eribulin Mesylate Versus Observation in Triple Negative Breast Cancer Patients

> **NCT04502680** · PHASE2 · UNKNOWN · sponsor: **The First Affiliated Hospital with Nanjing Medical University** · enrollment: 100 (estimated)

## Conditions studied

- Triple Negative Breast Cancer

## Interventions

- **DRUG:** Eribulin Mesylate

## Key facts

- **NCT ID:** NCT04502680
- **Lead sponsor:** The First Affiliated Hospital with Nanjing Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-06
- **Primary completion:** 2023-06
- **Final completion:** 2024-06
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2020-08-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04502680

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04502680, "Maintenance Treatment With Eribulin Mesylate Versus Observation in Triple Negative Breast Cancer Patients". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT04502680. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*